Oncogenic activation of the RAS-RAF-MEK-ERK (MAPK) pathway through overactive growth factor signaling or oncogenic mutation within the RAS or RAF oncogenes is a central feature in a large number of cancers [1–3]. This evidence concerns the gene MAPK1 and cancer.